Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Foundation for Liver Research
With
Janssen-Cilag B.V.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients between 18 and 70 years of age, with a chronic hepatitis C - genotype 1 infection
Patients are naive, non-responders or relapsers to previous treatment with peginterferon or conventional interferon plus ribavirin combination therapy
High viral load (\>400,000 IU/ml)
Indication for antiviral therapy of hepatitis C according to current clinical guidelines
You may not be if
Decompensated cirrhosis (Child-Pugh Grade B or C)
Hepatic imaging (ultrasound, CT or MRI) with the evidence of hepatocellular carcinoma.
Females who are pregnant or breast-feeding
History or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigators, unsuitable for the study
Co-infections with human immunodeficiency virus (HIV) or Hepatitis B virus (HBV)
Presence of contra-indications for antiviral therapy with telaprevir:
Telaprevir is contraindicated when combined with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events. Telaprevir in contraindicated when combined with drugs that strongly induce CYP3A and thus may lead to lower exposure and loss of efficacy of Telaprevir. The contraindicated medications include the following:
